Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
Status:
Completed
Trial end date:
2017-03-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared
to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia.
Phase:
Phase 3
Details
Lead Sponsor:
Paratek Pharmaceuticals Inc
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination